Stockscreener 앱 받기
55.31
4.12%
2.19
시간 외 거래:
55.31
Bio Techne Corp 주식(TECH)의 최신 뉴스
What analysts say about Bio Techne Corporation stockTriple returns potential - jammulinksnews.com
Bio Techne Corporation Stock Analysis and ForecastFree Investment Community - Autocar Professional
Bio-Techne Corporation shares rise 1.99% after-hours as US stocks close higher. - AInvest
Bio-Techne Corp. stock underperforms Monday when compared to competitors - MarketWatch
Envestnet Asset Management Inc. Sells 66,478 Shares of Bio-Techne Corp (NASDAQ:TECH) - Defense World
Bio-Techne’s Quarterly Earnings Preview: What You Need to Know - inkl
Bio-Techne’s Quarterly Earnings Preview: What You Need To Know - Barchart.com
Bio-Techne Schedules Q4 2025 Earnings Call: Full Fiscal Year Results Coming August 6 - Stock Titan
Bio-Techne to distribute Spear Bio’s ultrasensitive immunoassays - Yahoo Finance
Bio-Techne Corp (NASDAQ:TECH) Stake Lessened by M&T Bank Corp - Defense World
Analysts Set Bio-Techne Corp (NASDAQ:TECH) Price Target at $70.00 - Defense World
Why Bio Techne Corporation stock attracts strong analyst attentionProfitable Yet Secure Picks - Newser
How Bio Techne Corporation stock performs during market volatilityFree Expert-Led Investment Training - Newser
What makes Bio Techne Corporation stock price move sharplyOptimized Return Investment Picks - Newser
Here’s Headwaters Capital Management’s Investment Thesis for Bio-Techne (TECH) - Yahoo Finance
Spear Bio partners with Bio-Techne to expand ultrasensitive assay access By Investing.com - Investing.com South Africa
Spear Bio partners with Bio-Techne to expand ultrasensitive assay access - Investing.com
Bio-Techne Secures 1000x More Sensitive Biomarker Detection Technology in Major Neuroscience Partnership - Stock Titan
Bio-Techne (TECH) Partners with Spear Bio for Advanced Biomarker Detection | TECH Stock News - GuruFocus
Revolutionary Alzheimer's Biomarker Detection: Bio-Techne's New Platform Achieves 1000x Higher Sensitivity - Stock Titan
Bio-techne’s technology supports FDA approval of rare skin disorder therapy - Investing.com
Bio-Techne's Simple Western Enables Breakthrough FDA Approval for Rare Skin Disease Gene Therapy - Stock Titan
Teacher Retirement System of Texas Makes New Investment in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Bio-Techne Corp (NASDAQ:TECH) Shares Sold by Principal Financial Group Inc. - Defense World
Teacher Retirement System of Texas Acquires New Holdings in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Scotiabank Has Lowered Expectations for Bio-Techne (NASDAQ:TECH) Stock Price - Defense World
Scotiabank Maintains Buy Rating for Bio-Techne with $75 Price Target - AInvest
Bio-Techne stock price target lowered to $75 by Scotiabank - Investing.com Canada
TD Cowen Begins Coverage on Bio-Techne (NASDAQ:TECH) - Defense World
Minnesota's highest-paid CEOs made 7% more, with highest paid making $59.4M - Star Tribune
Assessing Bio-Techne: Insights From 7 Financial Analysts - Benzinga
Bio-Techne (TECH) Receives Buy Rating with $65 Price Target from TD Cowen | TECH Stock News - GuruFocus
Bio-Techne (TECH): TD Cowen Initiates Coverage with Buy Rating | - GuruFocus
Vontobel Holding Ltd. Decreases Stake in Bio-Techne Corp (NASDAQ:TECH) - Defense World
5 Revealing Analyst Questions From Bio-Techne’s Q1 Earnings Call - Yahoo Finance
Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch
GAMMA Investing LLC Cuts Stake in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Amalgamated Bank Purchases 222 Shares of Bio-Techne Corp (NASDAQ:TECH) - Defense World
Is There Now An Opportunity In Bio-Techne Corporation (NASDAQ:TECH)? - Yahoo Finance
How To Trade (TECH) - news.stocktradersdaily.com
Janney Montgomery Scott LLC Grows Stake in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock - Yahoo Finance
Bio-Techne stock holds steady as Stifel maintains $60 price target - Investing.com
Bio-Techne, USP Partner to Enhance Monoclonal Antibody, Gene Therapy Development - Insider Monkey
Major Breakthrough: Bio-Techne and USP Join Forces to Transform Gene Therapy Development Process - Stock Titan
First Week of August 15th Options Trading For Bio-Techne (TECH) - Nasdaq
Bio-Techne (NASDAQ:TECH) stock performance lags Nasdaq Composite in recent years - Kalkine Media
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
How the (TECH) price action is used to our Advantage - news.stocktradersdaily.com
Bio-Techne Director Cashes Out in Significant Stock Sale - TipRanks
Bio-Techne at Goldman Sachs Conference: Strategic Growth Amid Challenges - Investing.com
TECH Q1 Earnings Call: Management Highlights Market Uncertainties and Strategic Mitigation Efforts - Yahoo Finance
Transcript : Bio-Techne Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - MarketScreener
Bio-Techne To Present At Goldman Sachs Global Healthcare Conference; Webcast At 10:40 AM ET - Nasdaq
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics - Yahoo Finance
Bio-Techne (TECH) Maintains 'Buy' Rating with $75 Price Target | TECH Stock News - GuruFocus
Benchmark maintains Buy rating on Bio-Techne stock amid tariff impact By Investing.com - Investing.com South Africa
Benchmark maintains Buy rating on Bio-Techne stock amid tariff impact - Investing.com India
Stochastic Optical Reconstruction Miicroscope Market Size, - openPR.com
4.91%
0.25%
자본화:
|
볼륨(24시간):